Corcept Therapeutics Inc
CORT71.880USD
-0.130-0.18%
終値 07/11, 16:00（ET）15分遅れの株価
7.62B時価総額
56.85直近12ヶ月PER
詳細情報 Corcept Therapeutics Inc 企業名
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
企業情報
企業コードCORT
会社名Corcept Therapeutics Inc
上場日Apr 15, 2004
設立日1998
最高経営責任者「CEO」Dr. Joseph K. Belanoff, M.D.
従業員数500
証券種類Ordinary Share
決算期末Apr 15
本社所在地101 Redwood Shores Parkway
都市REDWOOD CITY
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号94065
電話番号16506888803
ウェブサイトhttps://www.corcept.com/
企業コードCORT
上場日Apr 15, 2004
設立日1998
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.98M
-1.34%
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.35M
+5.82%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.26M
--
Dr. Hazel Hunt, Ph.D.
Dr. Hazel Hunt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
183.41K
+54.67%
Mr. Sean Maduck
Mr. Sean Maduck
President - Corcept Endocrinology
President - Corcept Endocrinology
107.40K
--
Mr. Gary Charles (Charlie) Robb
Mr. Gary Charles (Charlie) Robb
Chief Business Officer, Secretary
Chief Business Officer, Secretary
35.79K
-4.90%
Mr. Atabak Mokari
Mr. Atabak Mokari
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
14.06K
+7.91%
Mr. Joseph Douglas Lyon
Mr. Joseph Douglas Lyon
Chief Accounting and Technology Officer
Chief Accounting and Technology Officer
10.07K
--
Mr. William Guyer, Pharm.D.
Mr. William Guyer, Pharm.D.
Chief Development Officer
Chief Development Officer
5.49K
--
Mr. Gregg Huber Alton, J.D.
Mr. Gregg Huber Alton, J.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Joseph K. Belanoff, M.D.
Dr. Joseph K. Belanoff, M.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
2.98M
-1.34%
Mr. James N. (Jim) Wilson
Mr. James N. (Jim) Wilson
Independent Chairman of the Board
Independent Chairman of the Board
2.35M
+5.82%
Mr. David L. Mahoney
Mr. David L. Mahoney
Independent Director
Independent Director
1.26M
--
Dr. Hazel Hunt, Ph.D.
Dr. Hazel Hunt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
183.41K
+54.67%
Mr. Sean Maduck
Mr. Sean Maduck
President - Corcept Endocrinology
President - Corcept Endocrinology
107.40K
--
Mr. Gary Charles (Charlie) Robb
Mr. Gary Charles (Charlie) Robb
Chief Business Officer, Secretary
Chief Business Officer, Secretary
35.79K
-4.90%
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Sat, May 17
更新時刻: Sat, May 17
株主統計
種類
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
12.28%
The Vanguard Group, Inc.
9.39%
Ingalls & Snyder LLC (Asset Management)
7.30%
Renaissance Technologies LLC
5.79%
Baker (George Leonard Jr.)
5.01%
Other
60.23%
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
12.28%
The Vanguard Group, Inc.
9.39%
Ingalls & Snyder LLC (Asset Management)
7.30%
Renaissance Technologies LLC
5.79%
Baker (George Leonard Jr.)
5.01%
Other
60.23%
種類
株主統計
比率
Investment Advisor/Hedge Fund
35.90%
Investment Advisor
31.21%
Individual Investor
11.55%
Hedge Fund
8.44%
Research Firm
1.58%
Pension Fund
1.03%
Sovereign Wealth Fund
0.82%
Bank and Trust
0.51%
Family Office
0.06%
Other
8.89%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
722
96.66M
91.15%
-8.10M
2025Q1
746
97.45M
92.10%
-9.12M
2024Q4
673
98.29M
93.20%
-10.89M
2024Q3
625
101.82M
97.42%
-10.51M
2024Q2
589
103.22M
99.09%
-12.69M
2024Q1
582
107.51M
103.94%
+2.98M
2023Q4
555
98.31M
95.40%
-4.22M
2023Q3
540
96.45M
94.14%
-5.68M
2023Q2
523
94.35M
92.83%
-12.18M
2023Q1
528
100.60M
93.30%
-751.20K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
BlackRock Institutional Trust Company, N.A.
13.02M
12.28%
-611.02K
-4.48%
Mar 31, 2025
The Vanguard Group, Inc.
9.96M
9.39%
-133.66K
-1.32%
Mar 31, 2025
Ingalls & Snyder LLC (Asset Management)
7.74M
7.3%
-357.16K
-4.41%
Mar 31, 2025
Renaissance Technologies LLC
6.14M
5.79%
-55.57K
-0.90%
Mar 31, 2025
Baker (George Leonard Jr.)
5.31M
5.01%
--
--
Apr 17, 2025
Parallel Advisors, LLC
3.97M
3.75%
+142.78K
+3.73%
Mar 31, 2025
State Street Global Advisors (US)
3.40M
3.21%
-146.42K
-4.13%
Mar 31, 2025
Belanoff (Joseph K)
2.98M
2.81%
-40.35K
-1.34%
Apr 17, 2025
Wilson (James N)
2.35M
2.21%
+129.14K
+5.82%
Apr 17, 2025
Geode Capital Management, L.L.C.
2.26M
2.13%
+191.89K
+9.28%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sun, Jul 6
更新時刻: Sun, Jul 6
銘柄名
比率
SPDR S&P Pharmaceuticals ETF
5.35%
Invesco S&P SmallCap Health Care ETF
5.17%
Pacer US Small Cap Cash Cows Growth Leaders ETF
4.73%
Formidable ETF
4.13%
Invesco Pharmaceuticals ETF
3.79%
First Trust NYSE Arca Biotechnology Index Fund
3.55%
iShares U.S. Pharmaceuticals ETF
3.46%
Invesco S&P SmallCap Momentum ETF
3.09%
Invesco S&P SmallCap Quality ETF
2.96%
Invesco S&P SmallCap 600 Pure Growth ETF
1.9%
詳細を見る
SPDR S&P Pharmaceuticals ETF
比率5.35%
Invesco S&P SmallCap Health Care ETF
比率5.17%
Pacer US Small Cap Cash Cows Growth Leaders ETF
比率4.73%
Formidable ETF
比率4.13%
Invesco Pharmaceuticals ETF
比率3.79%
First Trust NYSE Arca Biotechnology Index Fund
比率3.55%
iShares U.S. Pharmaceuticals ETF
比率3.46%
Invesco S&P SmallCap Momentum ETF
比率3.09%
Invesco S&P SmallCap Quality ETF
比率2.96%
Invesco S&P SmallCap 600 Pure Growth ETF
比率1.9%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
